Pap Smear vs HPV Test: What Each Detects and the New Screening Intervals

The small white box arrived in a friend’s mail last spring, somewhere between a seed catalog and a utility bill. Inside was a slim swab, an instruction card, and the promise that she could screen for cervical cancer in her own bathroom. She texted a photo with one question: is this real?

It is. As of January 2026, the hpv test has become the most searched cervical screening phrase in the United States, driven by three things that landed close together: the FDA’s 2024 decision to allow self-collected samples in clinics, its 2025 authorization of the first at-home collection kit, and a proposed national guideline update that would make HPV testing every five years the preferred approach for most adults aged 30 to 65.

Underneath the headlines sits a quieter story. The Pap smear is not disappearing. The two tests simply look for different things, at different points in a slow-moving disease, and understanding that difference explains why the calendar is changing.

What does HPV stand for, and why does one virus define a cancer screening test?

HPV stands for human papillomavirus, a family of more than 200 related viruses that infect skin and the moist lining of the body. Most types are harmless or cause ordinary warts. Around 14 are labeled high-risk because they can push cervical cells toward cancer over many years. Two of them, HPV 16 and HPV 18, are responsible for roughly 70 percent of cervical cancers worldwide, according to the World Health Organization.

The link is unusually tight. Virtually every cervical cancer, more than 99 percent in large tissue studies, contains high-risk HPV DNA. That makes cervical cancer different from, say, breast or colon cancer, where no single cause dominates. If you can find the virus, you have found almost everyone at meaningful risk, and if the virus is absent, risk over the next several years is very low.

Here is the part that often surprises people: HPV is extremely common. The CDC estimates that most sexually active people acquire at least one HPV infection in their lifetime, and most never know it. The immune system clears the majority of infections within one to two years without any treatment. Only a persistent infection with a high-risk type, lasting years rather than months, sets off the chain of cell changes that screening is designed to catch.

That timeline is the hidden reason both tests work at all. Cervical cancer usually takes 10 to 20 years to develop from a persistent infection, moving through stages of precancer that can be treated. The Pap smear looks at those cell changes once they appear. The HPV test looks one step upstream, at the infection that drives them. Everything else in this article follows from that single distinction.

What is a Pap smear, and what does it actually look for?

The Pap smear, named for the Greek-American physician George Papanicolaou who developed it in the 1940s, is a cytology test: cytology means examining individual cells under a microscope. During a pelvic exam, a clinician inserts a speculum, then uses a small brush or spatula to collect cells from the cervix, the narrow opening at the bottom of the uterus. The cells are rinsed into a liquid vial or smeared on a slide and sent to a laboratory.

There, a cytotechnologist or pathologist scans thousands of cells looking for shapes that are wrong: nuclei too large or too dark, cells that have lost their orderly arrangement. Results come back in a standardized vocabulary. A normal result is reported as negative for intraepithelial lesion. Mild uncertainty is called ASC-US, short for atypical squamous cells of undetermined significance. More definite changes are graded as low-grade or high-grade squamous intraepithelial lesions, often abbreviated LSIL and HSIL.

The Pap’s achievement is hard to overstate. In countries that adopted it widely, cervical cancer deaths fell by more than half over several decades, a public health success the National Cancer Institute describes as one of the most effective screening programs ever introduced.

Its weakness is sensitivity, meaning how often it correctly flags someone who truly has significant precancer. A single Pap detects roughly half to three quarters of high-grade lesions. Cells can be missed in collection, obscured by blood or inflammation, or simply overlooked among thousands of normal ones. Programs compensated by repeating the test often, originally every year. That frequency, rather than any single test, is what made cytology-based screening work.

What does an HPV test detect, and how is it different?

An HPV test is a molecular test. Rather than judging cells by their appearance, it searches the sample for genetic material from high-risk HPV types. The sample is collected the same way as a Pap, often from the very same vial of liquid, which is why the two can be run together as a cotest without a second exam.

Two laboratory approaches dominate. DNA-based tests look for the viral genome itself, usually across a panel of 13 or 14 high-risk types. Several also report genotyping, which means identifying specific types, most often HPV 16 and 18, because those two carry the highest risk. The second approach detects messenger RNA (mRNA), the working copies a virus makes when it is actively producing proteins. The Aptima HPV assay belongs to this group: it detects mRNA from the E6 and E7 genes of 14 high-risk types. E6 and E7 are the viral genes that disable a cell’s normal growth controls, so finding their mRNA signals an infection that is actively doing the kind of damage that matters.

Either way, the result is simpler than a Pap report: positive or negative for high-risk HPV, sometimes with a note on which type.

The HPV test’s strength is the mirror image of the Pap’s weakness. Its sensitivity for high-grade precancer is around 90 to 95 percent, because it does not depend on a human eye catching a few abnormal cells. Its limitation is specificity: it flags many transient infections that would have cleared on their own, especially in younger people. That trade-off is exactly why guidelines pair it with age limits and longer intervals, which the following sections unpack.

What changed recently in cervical screening

Four developments, all within roughly two years, explain the current surge of interest.

In May 2024, the US Food and Drug Administration expanded the approved labeling of two HPV tests to permit self-collected vaginal samples in healthcare settings, such as a clinic restroom, rather than requiring a clinician to collect cells with a speculum. The CDC’s screening guidance now describes self-collection as an option for people aged 30 to 65 who prefer it.

In December 2024, the US Preventive Services Task Force released a draft update of its 2018 recommendation. The draft keeps Pap testing every three years for ages 21 to 29 but, for ages 30 to 65, names primary HPV testing every five years as the preferred strategy, explicitly includes self-collected samples, and keeps cotesting and Pap alone as acceptable alternatives. A draft is not final guidance; it signals direction while the public comment and review process runs.

In May 2025, the FDA authorized the first device intended for at-home collection of a cervical screening sample, to be used with a prescription and mailed to a laboratory. The sample is tested for high-risk HPV; it is not a Pap, since home swabs do not reliably gather cervical cells for cytology.

Outside the United States, England’s National Health Service announced in June 2025 that people aged 25 to 49 who test negative for HPV will move from a three-year to a five-year recall, matching Scotland, Wales and the practice already standard for ages 50 to 64. The WHO’s 2021 guideline, which recommends HPV DNA testing as the preferred primary screening method globally, provided the evidence foundation for all of these changes.

Pap smear vs HPV test: a side-by-side comparison

Laid out together, the two tests look less like rivals and more like two instruments measuring different stages of the same process.

Feature	Pap smear (cytology)	HPV test (molecular)
What it detects	Abnormal cervical cells already present	DNA or mRNA of high-risk HPV types that cause those changes
Point in the disease	Downstream: cell changes	Upstream: the persistent infection
Sensitivity for high-grade precancer	Roughly 50–75% per test	Roughly 90–95% per test
False-positive tendency	Lower	Higher, especially under age 30
Typical interval when used alone	Every 3 years	Every 5 years
Usual starting age	21 (USPSTF)	25 (American Cancer Society) or 30 (USPSTF)
Sample collection	Clinician with speculum	Clinician, or self-collected swab in clinic or at home
Result format	Graded cell categories (ASC-US, LSIL, HSIL)	Positive or negative, sometimes with genotype
Main role in current guidelines	Primary test under 30; follow-up (reflex) test after a positive HPV result	Preferred primary test from 30 (or 25)

Two patterns stand out. First, the HPV test earns its longer interval by missing fewer cases; a negative result is more reassuring than a negative Pap, so it can safely be repeated less often. Second, the Pap has not lost its job. In most modern algorithms it is run on the same sample when HPV comes back positive, a step called reflex cytology, to decide who needs a closer look and who can simply be rechecked in a year.

The table also hints at why the starting age differs. Under 25, HPV infections are common and overwhelmingly temporary; testing for them would send many healthy young people to follow-up procedures for changes that would have resolved on their own.

What the evidence actually says, and how strong it is

The shift toward HPV-first screening rests on evidence most screening changes never get: large randomized trials with cancer as the outcome.

Strongest tier, randomized trials. A 2014 pooled analysis in The Lancet combined four European trials with more than 175,000 participants followed for a median of six and a half years. HPV-based screening provided 60 to 70 percent greater protection against invasive cervical cancer than cytology, with the benefit appearing from about two and a half years after enrollment. In rural India, a cluster-randomized trial of more than 130,000 women found that a single round of HPV testing reduced deaths from cervical cancer by roughly half compared with no screening, something a single round of cytology did not achieve. Canada’s HPV FOCAL trial, published in 2018, showed that people screened with a primary HPV test had significantly less high-grade precancer four years later than those screened with cytology, consistent with HPV testing finding lesions earlier.

Strong observational data. A US cohort of more than 330,000 people showed that a negative HPV test predicted a lower risk of high-grade precancer over five years than a negative Pap predicted over three. This is the direct basis for the five-year interval.

Self-collection, meta-analysis of trials and comparison studies. A 2018 BMJ review of 56 studies found that when a PCR-based assay is used, self-collected vaginal samples detect high-grade precancer about as well as clinician-collected samples. Older signal-amplification assays performed less well, which is why only specific tests are approved for self-sampling.

Weaker or evolving evidence. Whether at-home mailing changes long-term cancer outcomes is not yet proven; trials show it increases participation among people overdue for screening, which is an intermediate outcome. The optimal exit age and how to screen people fully vaccinated in childhood remain areas of modeling and expert opinion rather than trial data.

The new screening intervals by age: how often should you have an HPV test or Pap?

Intervals depend on age and which test is used, and the major US guidelines differ slightly. The following reflects the 2018 USPSTF recommendation, its 2024 draft update, and the 2020 American Cancer Society guideline, as summarized by the National Cancer Institute.

• Under 21: no screening, regardless of sexual history. Cervical cancer is extremely rare at this age and HPV infections almost always clear.
• Ages 21 to 24: USPSTF recommends a Pap every three years. The American Cancer Society recommends waiting until 25 to begin.
• Ages 25 to 29: USPSTF continues Pap every three years. The American Cancer Society prefers a primary HPV test every five years from 25.
• Ages 30 to 65: three acceptable options under USPSTF: primary HPV test every five years, cotest (HPV plus Pap on the same sample) every five years, or Pap alone every three years. The 2024 draft names primary HPV every five years as preferred, including self-collected samples.
• Over 65: screening can stop if the previous 10 years included adequate negative results (typically three consecutive negative Paps or two consecutive negative HPV or cotests, with the most recent within five years) and no history of high-grade precancer in the past 25 years.

Outside the US, England screens ages 25 to 49 and, from 2025, recalls people who test HPV negative every five years, while ages 50 to 64 have long been on five-year recall. Australia uses a five-year HPV test from 25 to 74.

Two caveats matter more than the exact numbers. Intervals apply only after a negative result; any positive result moves you onto a follow-up schedule set by your clinician. And a longer interval is not a looser standard. It reflects a more sensitive test, and it depends on actually returning when the next date arrives. Your clinician will tell you which schedule applies to your history.

Primary HPV, cotest, or Pap alone: which approach do clinics use at 30 and over?

Three screening strategies exist for adults aged 30 to 65, and it helps to know which one you are actually receiving, because the follow-up logic differs.

Primary HPV testing means the HPV test is run first and alone. If negative, you are done for five years. If positive, the laboratory typically performs reflex cytology, reading a Pap from the same vial, and often genotyping for HPV 16 and 18. Those two pieces of information decide whether you proceed to colposcopy or return in a year. This is the approach the WHO recommends, the one most of Europe, Australia and the UK use, and the one the 2024 USPSTF draft prefers.

Cotesting runs both tests on every sample regardless of result. It was the American standard for over a decade and remains acceptable every five years. Large US data sets show it adds very little detection over HPV testing alone, because almost all significant lesions found by the Pap in a cotest also test HPV positive. What cotesting adds is more abnormal Pap results that turn out to be unimportant, and therefore more follow-up.

Pap alone every three years is still an option, particularly where molecular testing is not available. It remains effective when repeated faithfully.

In practice, many US laboratories have moved to primary HPV with reflex cytology because it concentrates effort where risk is highest. Modern follow-up decisions use what the 2019 American Society for Colposcopy and Cervical Pathology consensus calls risk-based management: instead of acting on a single result, clinicians estimate your current risk of high-grade precancer using the present result and the past one, then match that risk to an action. Someone who was HPV negative five years ago and has a mild Pap finding today sits in a different category than someone with the same Pap finding and no screening history.

What does a positive HPV test result mean, including a positive Aptima result?

A positive result means high-risk HPV was detected in your sample. It does not mean you have cancer, and in most cases it does not mean you have precancer either. Most people with a positive test have an infection the body will clear, and the purpose of the result is to decide how closely to watch.

If your report names the Aptima assay, a positive result specifically indicates that mRNA from the E6 and E7 genes of one of 14 high-risk types was detected. Because mRNA reflects active viral gene expression rather than mere presence of viral DNA, a positive Aptima result tends to be slightly more specific for infections that are biologically active. Some Aptima reports also include a separate genotype result for HPV 16 and for 18 or 45. A negative Aptima result means no high-risk mRNA was found and risk over the next several years is low.

What happens next depends on three things: which type was found, what the Pap from the same sample shows, and your prior results.

• HPV 16 or 18 positive: referral for colposcopy is usually recommended regardless of the Pap, because these types carry the highest risk.
• Other high-risk type positive with a normal Pap: a repeat cotest in one year is typical, since most of these infections clear.
• Other high-risk type positive with an abnormal Pap: colposcopy is usually advised.

Colposcopy is an office procedure in which a clinician examines the cervix with a magnifying instrument and may take a small tissue sample, called a biopsy, for a definitive diagnosis. Only a biopsy can confirm precancer. A positive HPV test is a risk marker that points toward or away from that step; it is never a diagnosis on its own, and the interpretation belongs to the clinician who knows your full history.

What happens after an abnormal result, and why most people do not need treatment

The funnel narrows quickly. Among adults aged 30 and over, roughly 5 to 10 percent test positive for high-risk HPV at any screening round. A smaller share has an abnormal Pap at the same time. Of those referred to colposcopy, a minority are found to have high-grade precancer, and only a small fraction of untreated high-grade precancer would ever progress to invasive cancer. Screening works by finding that small group early, and the system is deliberately built to tolerate many false alarms to do it.

If colposcopy and biopsy show low-grade changes, known as CIN 1 (cervical intraepithelial neoplasia grade 1), the usual plan is observation, because most CIN 1 regresses on its own within two years. High-grade changes, CIN 2 or CIN 3, are often treated with an office procedure that removes or destroys the abnormal area; for some younger people with CIN 2, careful observation is an acceptable alternative because regression is common. After treatment, follow-up testing continues for years, since risk stays elevated.

Several facts help put a positive result in proportion. The immune system clears about 90 percent of new HPV infections within two years. Clearance means the virus becomes undetectable; whether it is eliminated or suppressed to undetectable levels is still debated, but either way the cancer risk falls. Infections that persist beyond two years are the ones that warrant closer attention, which is why a one-year repeat test is such a common instruction.

One more point deserves plain language: a positive HPV test in a long-term relationship does not indicate recent infidelity. HPV can remain dormant and undetectable for years, then become detectable again, and a positive result cannot be dated. Clinicians hear this worry often, and the biology does not support it.

Self-collection and at-home HPV tests: how they work and what the evidence shows

Self-collection means you insert a soft swab or brush a few centimeters into the vagina, rotate it as directed, and place it in a tube. It does not reach the cervix the way a clinician’s speculum exam does, which is precisely why it works only for HPV testing: the virus sheds into vaginal secretions, so a vaginal swab captures it, while cervical cells for a Pap are not reliably collected this way.

Two settings now exist in the United States. Since 2024, people aged 30 to 65 can self-collect in a healthcare facility, with the sample run on an approved PCR-based assay. Since 2025, a prescription-based device allows collection at home for ages 25 to 65, with the kit mailed to a laboratory. In both settings a positive result leads to the same follow-up as a clinician-collected positive: a clinic visit, usually for a Pap and possibly colposcopy. At-home testing shortens the first step; it does not replace the rest of the pathway.

The evidence for accuracy is solid. The 2018 BMJ meta-analysis found PCR-based self-samples matched clinician samples in detecting high-grade precancer, with sensitivity above 90 percent. The Netherlands, Australia and parts of Scandinavia have offered self-sampling within organized programs for several years, and randomized studies there show that mailing kits to people overdue for screening increases participation, often doubling response rates compared with another reminder letter.

What the evidence has not yet shown is a reduction in cancer deaths specifically attributable to at-home collection; the trials measured participation and lesion detection. There are also practical cautions. A home kit does not include the pelvic exam that can identify other conditions. Sample errors, such as insufficient material, require recollection. And people under 25, those with a history of high-grade precancer, or anyone with symptoms should be screened in person. Whether home collection suits you is a conversation for your clinician.

Who needs a different screening plan: hysterectomy, vaccination, immune conditions and age

Standard intervals assume an average-risk person with a cervix and a normal immune system. Several groups fall outside that frame.

After a total hysterectomy, surgery that removes the uterus and cervix, routine cervical screening is no longer needed if the operation was for a non-cancerous reason and there was no prior high-grade precancer. A partial hysterectomy that leaves the cervix in place does not change the screening schedule. The surgical record settles this, so it is worth confirming which type you had.

People living with HIV, organ transplant recipients, and others with significant immune suppression are advised to screen more often, often starting within a year of diagnosis or sexual debut and continuing beyond age 65, because persistent HPV infection is more common and progression is faster. Exposure before birth to diethylstilbestrol (DES), a hormone prescribed to some pregnant women before 1971, also warrants ongoing screening. Guidelines for these groups come from specialist societies, and the schedule should be set individually.

Vaccinated adults currently follow the same schedule as everyone else. Vaccination prevents infection with the types it covers but not all high-risk types, and most adults vaccinated so far were vaccinated after some exposure. Modeling suggests screening intervals could eventually lengthen for cohorts vaccinated before exposure, but no US or UK guideline has made that change yet.

Pregnancy does not postpone screening that is due; a Pap or HPV test is safe during pregnancy, though colposcopy follow-up may be adjusted.

Finally, age 65 is a threshold, not a finish line. Stopping requires documented adequate negative screening in the prior decade. Someone who has not been screened in 15 years should not stop simply because of a birthday. Cervical cancer in older adults disproportionately occurs in people who left screening early.

How the HPV vaccine fits alongside screening

Vaccination and screening are complementary, not interchangeable. The vaccine prevents new infections with the HPV types it covers; screening finds the consequences of infections that have already occurred, including from types the vaccine does not cover.

In the United States, the CDC recommends routine HPV vaccination for all adolescents at ages 11 or 12, with vaccination able to begin at age 9. Catch-up vaccination is recommended for everyone through age 26 who was not adequately vaccinated earlier. For adults aged 27 to 45, the CDC does not recommend routine vaccination but supports shared clinical decision-making, a conversation between a person and their clinician about whether vaccination is likely to benefit them, given that most people in this age range have already been exposed to some HPV types. The WHO recommends vaccination as a priority for girls aged 9 to 14, before sexual debut, and the NHS offers it in secondary school, with catch-up available to those eligible until their 25th birthday.

The vaccine currently used in the US protects against nine HPV types, including 16 and 18 and five other high-risk types that together account for about 90 percent of cervical cancers, as well as the two types responsible for most genital warts.

The population data are already visible. Among US women in their early twenties, infections with the four types in the original vaccine fell by about 80 percent within a decade of the program’s introduction. Sweden, Denmark and England have each reported sharp reductions in high-grade precancer and, in women vaccinated at ages 12 or 13, invasive cervical cancer rates near zero in the first affected cohorts.

None of that changes today’s screening advice. A vaccinated adult still follows the standard interval. Any questions about whether vaccination is appropriate at your age belong with your clinician.

Common myths about the HPV test and Pap smear, corrected

Viral posts about cervical screening tend to repeat the same handful of misunderstandings. Here is what the evidence says about each.

Myth: a longer interval means the system is cutting corners. The five-year interval exists because a negative HPV test is a more reliable negative than a Pap. Observational data covering hundreds of thousands of people show the five-year risk of high-grade precancer after a negative HPV test is lower than the three-year risk after a negative Pap. The interval follows the test’s accuracy.

Myth: a positive HPV test means cancer. It means high-risk virus was detected. Most positives are transient infections that clear. Only a biopsy diagnoses precancer or cancer.

Myth: the Pap is being abolished. The Pap remains the primary test under 30 in US guidelines and is the standard reflex test after a positive HPV result. Its role has narrowed, not ended.

Myth: at-home kits are a full replacement for a visit. Home kits collect a sample for HPV testing only. A positive result still requires an in-person Pap or colposcopy, and the kit does not replace a pelvic exam or evaluation of symptoms.

Myth: vaccinated people do not need screening. The vaccine does not cover every high-risk type, and most adults were vaccinated after some exposure. Current guidelines screen vaccinated and unvaccinated adults identically.

Myth: a positive result in a long-term relationship proves infidelity. HPV can lie undetectable for years and reappear. A positive test cannot be dated and says nothing about recent behavior.

Myth: people who are not sexually active, or who have sex only with women, do not need screening. HPV spreads through skin-to-skin genital contact of any kind, and some people acquire it long before current circumstances. Anyone with a cervix in the screening age range is advised to screen.

When to see a doctor about cervical screening or symptoms

Screening is for people without symptoms. The moment symptoms appear, the question changes from routine screening to prompt evaluation, and the right test is whatever your clinician decides after examining you, not a kit from the mail. Both the NHS and the CDC list the following as reasons to arrange an appointment soon, regardless of when your last test was or what it showed:

• Vaginal bleeding after sex, between periods, or after menopause
• Unusual vaginal discharge, particularly if it is watery, blood-tinged or has a strong odor
• Persistent pelvic pain or pain during sex
• Any of the above together with unexplained weight loss, leg swelling, or difficulty urinating, which can indicate more advanced disease

These symptoms are far more often caused by infections, hormonal changes, polyps or benign conditions than by cancer. They are listed here because they need an examination, not because their presence indicates a diagnosis. Please do not use them as a self-assessment checklist or wait for a screening date.

Beyond symptoms, several situations warrant a conversation with your clinician rather than guesswork:

• You are unsure which screening strategy you are on or when your next test is due
• You received a positive HPV or abnormal Pap result and have not yet discussed follow-up
• You have missed follow-up after a previous abnormal result
• You are over 65 and cannot document adequate prior screening
• You have a condition affecting your immune system, a transplant, or HIV
• You had a hysterectomy and do not know whether the cervix was removed
• You are considering self-collection or an at-home kit and want to know whether you are eligible

Every decision in this article, from which test to have to how to respond to a result, belongs with the clinician who knows your history. The evidence sets the framework; your clinician applies it to you.

Frequently asked questions

What does HPV stand for?

HPV stands for human papillomavirus, a group of more than 200 related viruses that infect skin and mucous membranes. About 14 types are considered high-risk because persistent infection can lead to cervical and several other cancers over many years. HPV 16 and 18 cause roughly 70 percent of cervical cancers. Most infections cause no symptoms and clear on their own within one to two years.

What tests are done to detect HPV?

The main tests detect the genetic material of high-risk HPV types in a cervical or vaginal sample. DNA-based tests look for the viral genome and often identify types 16 and 18 specifically; mRNA-based tests, such as the Aptima assay, detect active viral gene expression. Samples can be collected by a clinician during a pelvic exam or, for approved assays, self-collected with a vaginal swab in a clinic or at home. There is no blood test for cervical HPV screening.

What does a positive HPV Aptima test result indicate?

A positive Aptima result means messenger RNA from the E6 and E7 genes of one of 14 high-risk HPV types was detected, indicating an active high-risk infection. It does not mean cancer or even precancer. Follow-up depends on which type was found, the Pap result from the same sample, and your previous results; options range from a repeat test in one year to colposcopy. Your clinician interprets the result in context.

What are 5 warning signs of cervical cancer?

Screening exists precisely because early cervical precancer causes no symptoms, so a list cannot replace testing. Symptoms that warrant a prompt appointment include bleeding after sex, bleeding between periods or after menopause, unusual or blood-tinged discharge, pelvic pain, and pain during sex. These are far more often caused by benign conditions, and none indicates a diagnosis on its own. Anyone with these symptoms should be examined rather than wait for a screening date.

Is an HPV test better than a Pap smear?

For adults aged 30 and over, an HPV test is more sensitive: it detects around 90 to 95 percent of high-grade precancers compared with roughly 50 to 75 percent for a single Pap, and randomized trials show greater protection against invasive cancer. The Pap remains the recommended primary test under 30, where HPV infections are common and transient, and it is the standard follow-up test when an HPV result is positive.

How often should I have an HPV test?

US guidelines recommend a primary HPV test every five years for ages 30 to 65 after a negative result, and the American Cancer Society extends that to ages 25 to 29. Cotesting with a Pap is also every five years, while a Pap alone is every three. Any positive or abnormal result moves you to a shorter follow-up schedule set by your clinician, and people with immune conditions screen more often.

Can a Pap smear detect HPV?

Not directly. A Pap smear examines cervical cells for abnormal shapes caused by HPV, so it can suggest infection indirectly, but it does not detect the virus itself. Only a molecular HPV test identifies viral DNA or mRNA. The two are often run from the same liquid sample, either together as a cotest or with the Pap performed as a reflex test after a positive HPV result.

Are at-home HPV tests accurate?

When paired with an approved PCR-based assay, self-collected vaginal swabs detect high-grade precancer about as well as clinician-collected samples, according to a 2018 meta-analysis of 56 studies. At-home kits test only for high-risk HPV; they cannot perform a Pap. A positive result requires an in-person visit for follow-up, and people with symptoms, a history of high-grade precancer, or significant immune suppression should be screened in person.

Do I still need a Pap smear if I had the HPV vaccine?

Yes. Vaccinated adults currently follow the same screening schedule as everyone else. The vaccine prevents infection with the types it covers, which cause about 90 percent of cervical cancers, but not all high-risk types, and most adults were vaccinated after some exposure. Modeling suggests intervals may lengthen for cohorts vaccinated before exposure, but no US or UK guideline has changed screening for vaccinated people yet.

What is the difference between a cotest and primary HPV testing?

Primary HPV testing runs the HPV test first and alone; the Pap is read from the same sample only if HPV is positive. A cotest runs both the HPV test and the Pap on every sample regardless of result. Both are performed every five years for ages 30 to 65. Large US data sets show cotesting adds little detection over HPV testing alone while generating more follow-up for unimportant Pap findings, which is why guidelines increasingly prefer the primary HPV approach.

References

• Screening for Cervical Cancer (CDC)
• Human Papillomavirus (HPV) Test (MedlinePlus)
• Cervical screening (NHS)
• Cervical cancer fact sheet (World Health Organization)

This article is for general information only and is not a substitute for professional medical advice. Please consult a qualified doctor about your individual situation.